Bachem stock holds its 2026 gains as peptide demand underpins outlook

Bachem Holding AG (CH0012530207) stock traded around CHF 77.15 at the close on August 21, 2026, on the Cboe venue, leaving the shares up 3.26% since January 1 and 28.35% higher for 2026 overall per recent market data. This price level reflects investor confidence that the Swiss peptide specialist can translate rising demand for active pharmaceutical ingredients into sustained revenue and earnings growth.

Shares consolidate after a strong 2026 run

Recent quote data for Bachem shows a last recorded Cboe price of CHF 77.15 at 11:20 a.m. ET on August 21, 2026, with a modest daily decline of 0.64% on that session. The same data set highlights that despite this small pullback, the stock remains 28.35% higher year to date, underlining how strongly the market has rewarded the company in 2026 so far. A 3.26% gain since the start of the year suggests that most of the outperformance has come in recent months as investors responded to improved operating trends and expectations for future orders. The resulting combination of a high-single-digit year-to-date move and a nearly 30% performance for 2026 indicates that the shares are trading well above levels seen at the turn of the year.

On the Swiss market, intraday prints in August 2026 show Bachem changing hands in a corridor between CHF 72.50 and CHF 72.75 in recent trades, with individual transactions ranging between 15 and 121 shares. This tighter intraday range on the home exchange compared with the Cboe reference price illustrates the normal dispersion that can arise between venues but still places the stock in the low-70s CHF band. For investors, that band now serves as a reference zone against the stronger CHF 77.15 level recorded on the Cboe close data, giving a sense of how trading liquidity and price discovery differ across markets.

Latest fundamentals and growth expectations

The latest interim financial reporting for Bachem in 2026, as reflected in current analyst consensus overviews, points to a continued focus on revenue growth and margin expansion in peptide and oligonucleotide manufacturing. Consensus tables for the stock attribute the pronounced 28.35% performance in 2026 to expectations that sales and earnings in the most recently reported half-year will improve from the prior year, driven by higher capacity utilization and new customer contracts. In that most recent reporting period within the 2026 financial year, analysts project that revenue and earnings per share will both show year-on-year increases, with consensus revenue growth expressed in the high-single-digit to low-double-digit percent range. The key comparison for investors is that estimated 2026 revenue outpaces the actual figures recorded in fiscal 2024, suggesting a meaningful acceleration.

Within these consensus tables, the contrast between 2026 estimates and earlier reported numbers stands out. For example, if revenue in the comparable 2025 period is taken as a base, current projections for 2026 indicate a clear step up, with mid- to high-single-digit percentage gains in sales alongside margin improvement, in turn lifting expected earnings per share. The result is a profile where the company is anticipated to grow faster in 2026 than it did in 2025, an expectation that helps explain why the stock price has advanced by more than 28% during 2026. For long-term holders, the implied acceleration in top-line and bottom-line metrics is central to the investment case.

Historical comparisons further reinforce this picture. In earlier fiscal years prior to 2025, Bachem reported lower revenue bases and more constrained earnings, reflecting the early stages of its capacity expansions and customer pipeline build-out. By contrast, the most recent 2026 interim period and related consensus figures show a larger revenue scale and higher profitability targets, with the step change expressed in double-digit percentage terms versus those older historical benchmarks. That shift from a smaller, capacity-constrained business to a larger, growth-oriented manufacturer is a major reason the equity market is assigning a higher valuation to the company in 2026.

Go deeper

More on Bachem stock

Recent consensus and performance tables for Bachem

Peptide and oligonucleotide CDMO business

Bachem generates its revenue by developing and manufacturing active pharmaceutical ingredients based on peptides and oligonucleotides, supplying biotechnology and pharmaceutical companies worldwide. The company operates as a contract development and manufacturing organization, offering services that span from early-stage development through commercial-scale production. Its facilities are designed to handle complex peptide chemistry and large-scale synthesis, allowing clients to outsource critical steps in their drug development pipelines.

Demand for these services has risen as more peptide-based and nucleic acid-based therapies move through clinical development. That pipeline expansion has translated into higher order intake for Bachem, which in turn supports the consensus expectations for revenue and earnings growth in the current 2026 reporting periods. The company has invested in additional production capacity in recent years to support large-volume commercial contracts, and higher utilization of that capacity is now a key lever behind the projected year-on-year improvement in profitability. For investors, the business model offers exposure to a broad range of therapeutic areas through a single manufacturing specialist, rather than relying on the success of any one drug.

Bachem stock and current valuation context

With a quoted level of CHF 77.15 on August 21, 2026, and a 28.35% share price increase for 2026, Bachem trades at a clear premium to where it stood at the start of the year. The quantitative comparison between the 3.26% gain since January 1 and the much higher 28.35% move over the 2026 period suggests that the strongest leg of the advance has taken place more recently alongside improving expectations in the consensus data. The consolidation in the low-70s CHF range on the Swiss market, set against the higher Cboe reference price, shows that while the stock has paused after its run, it remains well above prior trading ranges seen in earlier years.

For shareholders, the central question now is whether the company can deliver on the revenue and earnings growth embedded in those 2026 expectations. If the most recent interim results confirm high-single-digit to low-double-digit sales growth and improving margins versus the 2025 period, the current valuation implied by the low-70s CHF trading band and the CHF 77.15 reference price could be justified. Conversely, any disappointment in reported figures or guidance could see some of the 28.35% performance for 2026 retrace. For now, the combination of strong year-to-date gains, a solid uplift for 2026, and a business model aligned with growing peptide and oligonucleotide demand defines the Bachem equity story.

Fact box

Company: Bachem Holding AG

ISIN: CH0012530207

Ticker: BANB

Exchange: SIX Swiss Exchange

Price (as of August 21, 2026, 11:20 a.m. ET): CHF 77.15

Sector / Industry: Pharmaceuticals / Biotechnology manufacturing